Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Sees Significant Growth in Short Interest

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 85,300 shares, a growth of 5.7% from the November 30th total of 80,700 shares. Based on an average daily trading volume, of 70,100 shares, the days-to-cover ratio is currently 1.2 days. Currently, 7.8% of the company’s stock are sold short.

Cadrenal Therapeutics Price Performance

Shares of Cadrenal Therapeutics stock opened at $14.65 on Thursday. Cadrenal Therapeutics has a 1-year low of $5.40 and a 1-year high of $32.55. The business has a fifty day moving average price of $14.74. The firm has a market capitalization of $26.12 million, a PE ratio of -2.19 and a beta of 1.22.

Analyst Ratings Changes

Separately, HC Wainwright increased their price objective on Cadrenal Therapeutics from $3.00 to $32.00 and gave the company a “buy” rating in a report on Monday, November 11th.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.